These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7625752)

  • 1. Casodex: preclinical studies and controversies.
    Furr BJ
    Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
    [No Abstract]   [Full Text] [Related]  

  • 2. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
    Kolvenbag GJ; Furr BJ
    Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
    [No Abstract]   [Full Text] [Related]  

  • 4. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A; von Angerer E
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

  • 8. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 9. Bicalutamide ('Casodex') development: from theory to therapy.
    Kolvenbag GJ; Furr BJ
    Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimated potency of Casodex: a problematic design.
    Labrie F; Simard J; Singh SM; Candas B
    Urology; 1997 Aug; 50(2):309-13. PubMed ID: 9255312
    [No Abstract]   [Full Text] [Related]  

  • 11. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
    Freeman SN; Mainwaring WI; Furr BJ
    Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
    Kemppainen JA; Wilson EM
    Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?
    Roach M; Reese D; Weinberg V; Small EJ; Carroll PR
    J Clin Oncol; 2000 Jan; 18(2):448-50. PubMed ID: 10637263
    [No Abstract]   [Full Text] [Related]  

  • 15. Bicalutamide versus flutamide in combination therapy.
    Labrie F; Candas B
    Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
    [No Abstract]   [Full Text] [Related]  

  • 16. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
    Furr BJ
    Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
    [No Abstract]   [Full Text] [Related]  

  • 17. Casodex--mechanisms of action and opportunities for usage.
    Blackledge G
    Cancer; 1993 Dec; 72(12 Suppl):3830-3. PubMed ID: 7504578
    [No Abstract]   [Full Text] [Related]  

  • 18. Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex.
    Waller AS; Sharrard RM; Berthon P; Maitland NJ
    J Mol Endocrinol; 2000 Jun; 24(3):339-51. PubMed ID: 10828827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.